The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | J | Antiinfectives for systemic use | |
2 | J05 | Antivirals for systemic use | |
3 | J05A | Direct acting antivirals | |
4 | J05AF | Nucleoside and nucleotide reverse transcriptase inhibitors |
Code | Title | |
---|---|---|
J05AF01 | Zidovudine | |
J05AF02 | Didanosine | |
J05AF03 | Zalcitabine | |
J05AF04 | Stavudine | |
J05AF05 | Lamivudine | |
J05AF06 | Abacavir | |
J05AF07 | Tenofovir disoproxil | |
J05AF08 | Adefovir dipivoxil | |
J05AF09 | Emtricitabine | |
J05AF10 | Entecavir | |
J05AF11 | Telbivudine | |
J05AF12 | Clevudine | |
J05AF13 |
Active Ingredient | Description | |
---|---|---|
Abacavir |
Abacavir is a NRTI. It is a potent selective inhibitor of HIV-1 and HIV-2. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). In vitro studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle. |
|
Adefovir dipivoxil |
Adefovir dipivoxil is an oral prodrug of adefovir, an acyclic nucleotide phosphonate analogue of adenosine monophosphate, which is actively transported into mammalian cells where it is converted by host enzymes to adefovir diphosphate. Adefovir diphosphate inhibits viral polymerases by competing for direct binding with the natural substrate (deoxyadenosine triphosphate) and, after incorporation into viral DNA, causes DNA chain termination. |
|
Didanosine |
Didanosine belongs to a class of medicines called nucleoside analogues or nucleoside reversetranscriptase inhibitors (NRTIs). Intracellularly, didanosine is converted by cellular enzymes to the active metabolite, dideoxyadenosine 5'-triphosphate. Dideoxyadenosine 5'-triphosphate inhibits the activity of HIV-1 reverse transcriptase both by competing with the natural substrate, deoxyadenosine 5'-triphosphate, and by its incorporation into viral DNA causing termination of viral DNA chain elongation. |
|
Emtricitabine |
Emtricitabine is a synthetic nucleoside analogue of cytidine with activity that is specific to HIV-1, HIV-2 and HBV. Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which competitively inhibits HIV-1 reverse transcriptase, resulting in DNA chain termination. Emtricitabine is a weak inhibitor of mammalian DNA polymerase α, β and ε and mitochondrial DNA polymerase γ. |
|
Entecavir |
Entecavir, a guanosine nucleoside analogue with activity against HBV polymerase, is efficiently phosphorylated to the active triphosphate (TP) form, which has an intracellular half-life of 15 hours. By competing with the natural substrate deoxyguanosine TP, entecavir-TP functionally inhibits the 3 activities of the viral polymerase: (1) priming of the HBV polymerase, (2) reverse transcription of the negative strand DNA from the pregenomic messenger RNA, and (3) synthesis of the positive strand HBV DNA. |
|
Lamivudine |
Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription. |
|
Stavudine |
Stavudine, a thymidine analogue, is phosphorylated by cellular kinases to stavudine triphosphate which inhibits HIV reverse transcriptase by competing with the natural substrate, thymidine triphosphate. It also inhibits viral DNA synthesis by causing DNA chain termination due to a lack of the 3'-hydroxyl group necessary for DNA elongation. Cellular DNA polymerase γ is also sensitive to inhibition by stavudine triphosphate, while cellular polymerases α and β are inhibited at concentrations 4,000-fold and 40-fold higher, respectively, than that needed to inhibit HIV reverse transcriptase. |
|
Telbivudine |
Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV DNA polymerase. It is efficiently phosphorylated by cellular kinases to the active triphosphate form. Incorporation of telbivudine-5'-triphosphate into viral DNA causes DNA chain termination, resulting in inhibition of HBV replication. |
|
Tenofovir disoproxil |
Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate analogue. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes. Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination. |
|
Zalcitabine |
Zalcitabine is a nucleoside analog reverse-transcriptase inhibitor (NRTI). |
|
Zidovudine |
Zidovudine is an antiviral agent which is highly active in vitro against retroviruses including the Human Immunodeficiency Virus (HIV). |
Title | Information Source | Document Type | |
---|---|---|---|
BARACLUDE Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
EMTRIVA Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
EMTRIVA Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
EPIVIR Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
Hepsera 10 mg tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
HEPSERA Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
Lamivudine 3TC Tablets | Health Products and Food Branch (CA) | MPI, CA: SPM | |
RETROVIR Capsules, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
RETROVIR Concentrate for solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
RETROVIR Oral solution/syrup | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
SEBIVO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
VEMLIDY Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
Videx EC 125mg, 200mg, 250mg and 400mg Gastro-resistant Capsules | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
VIREAD Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
ZEFFIX Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
ZERIT Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
ZERIT Powder for oral solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
ZIAGEN Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
ZIAGEN Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC |